Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

lutetium Lu-177 girentuximab

A radioimmunoconjugate consisting of the chimeric monoclonal antibody cG250 linked to the low energy beta-emitting radioisotope Lutetium 177, via the bifunctional macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), with potential antineoplastic activity. The antibody moiety of lutetium Lu-177-DOTA-chimeric monoclonal antibody cG250 binds to renal cell carcinoma (RCC) cells expressing the RCC-associated antigen G250; a cytotoxic dose of beta radiation is selectively delivered to G250-expressing RCC cells upon internalization of the radioimmunoconjugate.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:lutetium Lu-177-DOTA-chimeric monoclonal antibody cG250
lutetium-177 labeled cG250
Abbreviation:177Lu-DOTA-cG250
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search